# A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants

> **NCT07286370** · PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 537 (estimated)

## Conditions studied

- Salmonella Infections

## Interventions

- **BIOLOGICAL:** Low dose of iNTS-TCV
- **BIOLOGICAL:** Full dose of iNTS-TCV
- **BIOLOGICAL:** TYPHIBEV
- **COMBINATION_PRODUCT:** Prevenar 13
- **COMBINATION_PRODUCT:** Nimenrix
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT07286370
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-04-27
- **Final completion:** 2028-04-27
- **Target enrollment:** 537 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07286370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07286370, "A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07286370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*